PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known ubstitute for form 1449/PTO **Application Number** 09/700,101 **Filing Date** INFORMATION DISCLOSURE 11/8/2000 **First Named Inventor**

STATEMENT BY APPLICANT Glick, et al **Art Unit** 1618 (Use as many sheets as necessary) **Examiner Name** Kim, Vickie Y **Attorney Docket Number** Sheet UM-07268 of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
()-	1	Snyder, Jane R., Chemistry & Biol., 12, (2005), 477-484	
	2	Williams, Darren, Chemistry & Biol., 11, (2004), 1251-1259	
Examiner	\vdash	Date 2/2111	
Signature		Considered 3/30/56	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sheet 1

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	09/700, 101				
Filing Date	11/08/2000				
First Named Inventor	GLICK, et al				
Art Unit	1618				
Examiner Name	Kim, Vickie Y				
Attorney Docket Number	UM-07268				

			U. S. PATEN	T DOCUMENTS		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
1		US- 6,767,533	07/27/2004	Casellas	Whole Document	
Y-	2	^{US-} 6,506,744	01/14/2003	Alig	Whole Document	
U	-	US-	01/14/2000	7.119	VVIIOle Document	
	 	US-	- 			
	 	US-	<u> </u>			
	 	US-	- - **			
		US-	 			
		US-				
	<u> </u>	US-				
_		US-				
		US-			· ·	
		US-				
		US-				
		US-				
		US-				
		US-				
		US→				
		US-				
		US-				

		FOREIGN	PATENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ 'Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
	L					
	<u> </u>			•		
	<u> </u>				,	
Ĺ,		Ĺ	<u> </u>			

Examiner Signature	7/~	Date Considered	31 %	اچل
			,,	•

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	te for form 1449/PTO				Complete if Known			
	101011111111111111111111111111111111111			Application Number	09/700,101			
INF	ORMATION	DIS	CLOSURE	Filing Date	11/08/2000			
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Glick			
	// loo oo	4		Art Unit	1618			
	(Use as many she	ecis as n	recessary)	Examiner Name	Kim, Vickie Y.			
Sheet	2	of	2	Attorney Docket Number	UM-07268			

Examiner Initials*	xaminer Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issunumber(s), publisher, city and/or country where published.		T²
Y	3	Parks, Daniel J. Bioorg Med Chem. Ltrs,. 15,(2005), 765-770	
	4	Raboisson, P. Bioorg Med Chem. Ltrs., 15,(2005), 1857-1861	
	5	Hulme, C. J. Org. Chem., 63,(1998), 8021-8023	
	6	Kamal, A. Synlett, 14,(2004), 2533-35	
4	7	Grasberger, Bruce L., J. Med. Chem., 48, (2005), 909-912	
		-	
	•		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

SEP 0 6 2005

Examiner

Signature

PTC/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ersons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/700,101 INFORMATION DISCLOSURE **Filing Date** 11/08/2000 STATEMENT BY APPLICANT First Named Inventor Gary D. Glick et al. Art Unit Not Assigned (Use as many sheets as necessary) Examiner Name Not Assigned Sheet **Attorney Docket Number** UM-07268 1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
1		Beurdeley-Thomas et al., Journal of Neuro-Oncology 46 (2000) 45-56	
	2	Churcher et al., Bioorganic & Medicinal Chemistry Letters 13 (2003) 179-183	
	3	Darrow et al., Bioorganic & Medicinal Chemistry Letters 8 (1998) 3127-3132	
	4	Herranz, Medicinal Research Reviews 23 (2003) 559-603	
	5	Ramdas et al., Archieves of Biochemistry and Biophysics 368 (1999) 394-400	
1	6	Ursini et al., J. Med. Chem. 43 (2000) 3596-3613	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office			Attorney Docket No.: UM-07268 Serial No.: 09/700,101						
(Modified) Palent and Trademark Office									
INF	ORMATI	op niscussing	TATEMENT BY API	PLICANT					
	/	(Use Several Sheet					1		
	/		8						
(37 CFR ? 1.9)8(b))	APR 0 6 2305	빙				<u> </u>		
	/	Ē,	<u>\$</u>		Applicant: Gary D. Glick	et al.	,		
		THADE THAT	/		Filing Date: 11/08/2000		Group Art Unit	:	
		MAUE	γ	U.S. PATENT DOC	UMENTS	,	,	•	
Examiner	Cite	Serial / Patent	Issue Date	Applic	ant / Patentee	Class	Subclass	Filing	, Date
Initials	No.	Number	ļ			ļ			
N	1	5,776,946	07/07/1998	Mo	G ccr et al.	514	307	08/28	/1995
10	2_	5,288,514	2/22/940		Ellman	427	29.6	9/1	1/92
			FOREIGN PATENTS	OR PUBLISHED FOR	REIGN PATENT APPLICAT	TIONS			
		Document	Publication Date	Country	/ Patent Office	Class	Subclass	Trans	lation
		Number							
							ļ	Yes	No
V.	3	WO 99/29347	17 June 1999	<u> </u>	WO				
	4	WO 99/58117	18 Nov 1999		WO				ļ
<u> </u>	. 5	DE 1810423		G	iermany				
(<i>f</i>	6	EP 0 227 539 B1	11 Dec 1986	<u></u>	EPO				
			. <u>-</u>						
	L						<u> </u>	-	
- h	,	OTHE	R DOCUMENTS (Inc	luding Author, Title, D	ate, Relevant Pages, Place of	f Publication)			
	7	Walser et al., J. Org.	Chem. 38:3502-3507	(1973)					
	-8	Kim et al., J. Braz. C	Chem. Soc. 9:375-379 ((1998)					
	9	Schlumpf, M., et al.,	"Delayed Developmer	ntal Immunotoxicity of	Prenatal Benzodiazepines,"	Toxic. In Vitro - 8	3(5):1061-1065(19	94).	
		ļ <u>.</u>							
		ļ							
								· · ·	<u> </u>
	<u> </u>								
	l	-			r		- 1711-		
Examiner:			,		Date Considered:		006		
EXAMINER:	Init	tial citation considered.	Draw line through cit	ation if not in conform	ance and not considered. Inc	clude copy of this	form with next co	mmunicati	on to
annlicant									

		OiP	E				PTO/SB/08 (2/92) Sheet 1 of 1
Form PT	O-144	9 MAR 2	5 2002	Docket No. UM 2038.01		Appl. No. 09	
INFORMATION DISCLOSURE STATEMENT				Applicant(s)	Gary D. GLI		APR HCENT
		everal sheets if n		Filing Date: November 8, 2	2000	Group Art Ur	
				PATENT DOCUMEN	ITS		70072 70072 70072900
Examiner Initials	Ref.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
V	1.	08/21/01	6,277,844 B1	Spector et al.	-		
- (/ -	2.	11/20/01	6,319,931 B1	Kroemer et al.			 -
	-						
		L	FOREIG	ON PATENT DOCUM	IENTS		<u> </u>
Examiner Initials	Ref.	Date	Document No.	Name	Clas	Subclass	Translation YES NO
initials	No.						123 110
	 	· · · · · ·					
Examiner Initials	Ref. No.	Title					date, pertinent pages, etc.)
				•			
							· · · · · · · · · · · · · · · · · · ·
					 		
						,	
FVALUE		\		L DATE CON	CIDEDED: -	15 1	
EXAMINE)	DATE CON	- I	30/36	
EXAMINER: considered. 1	Initial if o	itation/considere copy of this form	d, whether or not the cita with next communication	ntion conforms with MPEP 609. In to applicant.	Draw a line through	In the Citation i	f not in conformance and no

Supplemental Form PTO-1449			m PTO-1449	Attorney's Docket No. 128019-203801 Application Serial No. 09/700,101				
DIES	D) EME	NTAL INCODMA	ATION DISCLOSURE	Applicant(s)	D. GLICK, e	tal.		
300	Lréinei S	STATEME	ENT	Ouly D. Octory of an				
7 7 1 20		several sheets	if necessary)	Filing Date: November 8, 2000	Gro	up Art Unit:	1614	
				US PATENTOCOUMETRS		(1)(本)(1)		
Initials			Document No.	Name	Class	Subclass	Filing Date (if appropriate)	
		y to a very series		OREIGNIPAMENTADOGUMENTIS 1885	· · · · · · · · · · · · · · · · · · ·			
Examino Initials	er Ref No.		Document No.	Name .	Class	Subclass	Translation YES NO	
	1.	01/07/89	0 349 949 A2	EPO				
2525572745	r i gest de				ricernal v	A CONTRACTOR		
			(ineludii	prauthor (itle, date, pertinent/pages, etc.				
Examino Initials	er Ref No.							
4	2.	Blum P., e	t al., "Stiff-Person Syn	drome: An Autoimmune Disease" <i>Moven</i> olines Induce Apoptotic Death of Cerebel	nent Disorder	s, <u>6</u> (1): 12-20) (1991)	
	3.	7 (18): 304	41-3045 (1996)					
	4.	Following	Transient Cerebral Iso	ines Prevent Neuronal Death By Apoptos chemia" <i>Society for Neuroscience Abstra</i>	cts, <u>24</u> (1-2):	979 (1998)		
	5.	1065 (1994	4)	velopmental Immunotoxicity of Prenatal I				
	6.	Mitochone	drial Transmembrane I	epine Receptor Agonists Modulate Thymo Potential" <i>Jpn. J. Pharmacol.</i> , <u>79</u> : 177-183	3 (1999)			
af	7.	Taupin V., the Produ 10 (1): 7-1	ction of Interleukin-1	Anxiogenic Peptide, ODN-Diazepam-Bindi and Tumor Necrosis Factor by Human Mo	ng Inhibitor, a nocytes" <i>Lyn</i>	and Benzodia aphokine and	zepines Enhance Cytokine Research,	
	_ _							
ļ								
							· · · · · · · · · · · · · · · · · · ·	
	_		·					

		.)		
EXAMINER:			DATE CONSIDERED:	3/20	ا د
EYAMINED: INIA	al 16 altast &	annoidened whether or not	the citation conforms with MDED 600 Draw	a line through the	itation if not in confo

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2/92) Sheet 1 of 1

Form P7	0-14	49		Docket No. 120	004000004	T A	Sheet 1 of		
AIPA	AIPA			Docket No. 128	019203801	Appl. No	Appl. No. 09/700,101		
MAR 1 9 2	204	IATION I STATEN	DISCLOSURE MENT	Applicant(s) Gary D. Glick					
A TRADEM	1 (See several sheets if necessary)			Filing Date: Nov	v. 8, 2000	Group Art Unit: Unassigned			
RADEM	~		U.S	. PATENT DOCUM	ENTS				
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)		
 _	T			GN PATENT DOCL	JMENTS				
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO		
			C	THER DOCUMEN		a outhor sister			
Examiner Initials	Ref. No.	Title	ternational Sparch	port for PCT/US00/4159		g author, title, (date, pertinent pages, etc.)		
			Deficit Ne	portion 1 C 1/0 S 0 0/4 1 3 5	1/25	B wo	-		
					()(-)	0.20	inet		
						100			
				· · · · · · · · · · · · · · · · · · ·					
						-1	:		
					- C	MAR 2			
						MAR 2 1 2001 TECH CENTER 1600/2900	RECEIVED		
						0			

EXAMINER:	
	DATE CONSIDERED: 212/16
EXAMINER: Initial if citation considered, whether or not the citation conforms	1 30 30 P
considered. Include a copy of this form with next communication to applicant.	with MPEP 609. Draw a line through the citation if not in conformance and not

IAN 1 6 2001

194749v1

PTO/SB/08 (2/92) Sheet 1 of 1

	nnlam	ental Form I		2001	attorney's Do	cket No. 128019-20	3801 App	lication Seria	al No. 09/70	0,101
3u	hhisiii	SILEI I VIIII	RE STATEMENT		Applicant(s)		D. GLICK, et	t ai.		
INFORM						November 8, 2000		up Art Unit:		
	e seve	ral sheets if	necessary)	SEU/SE	PATENTIDO	GUMENUS A		24/2/07		4914
	ef.	Date	Document No.	N	ame		Class	Subclass	(if approp	riate)
als N	0.					DOGUMENUS:/	THE PERSONS		79.66	W
	のが高度	Carlot Land		FORE	SNIPATIENT	DOGUNIZADO	Class	Subclass	Trans	lation
miner R	ef.	Date	Document No.	N	ame		Class	Jubilass	YES	NO
1		10/01/1990	0 349 949 A2		PO	Mange		party and		e for the
			dicelu	inglaut		IMEXION : 3.5. Perdinentiperies et	015.57			
miner F	Ref.	Title						,	20 (1991)	
	No 2.	Blum. P., et	al., "Stiff-Person	Syndron	ne: An Autoin	nmune Disease," Mo	vement Disord	1873 - 0(1). 14	tures." Neui	oRepor
	3.	Malgrange.	B., et al., "B-Carbo	olines in	auce wholion	ic beaution concerns	-			pus
1-1	4.	Miller, K.A., Following	et al., "Benzodiaz ransient Cerebral	epines l Ischem	Prevent Neuro ia,""Society fo	onal Death by Apopto or Neuroscience Abs	tracts - 24(1-2):979 (1998) pines." <i>Toxic</i>	c. In Vitro -	3(5):106
	5/	Schlumpf.	M., et al., "Delayed	Develo	pmentai illiilli	indicationly of 1 fortuna			Reduction	of the
1 /	6.	Mitochond	riai Transmembrai	ne Pote r	itial, Jpn. J.	onists Modulate Thyr Pharmacol. – 79:177-	diam labibito	and Benzo	diazepines (Enhance
V	7.	Taupin, V., the Produc - 10(1):7-1	et al., "Endogeno tion of Interleukin	us Anxid	umor Necros	Pharmacol. — <u>/9</u> :1//- e, ODN-Diazepam-Bii is Factor by Human I	Monocytes," L	ymphokine a	and Cytokine	Resea
		275								
										
										· · ·
										
_	<u> </u>									
					/					
		_=>	A			DATE CONSID	ERED:	न	30106	
EXAMINE		i if citation E	onsidered, whether	r or not (the citation co	nforms with MPEP 60 o applicant.	9. Draw a line	through the	citation if n	ot in co
not consid	lered. I	nctude a cop	onsidered, whether y of this form with	next cor	nmunication t	o applicant				

PTO/SB/08 (2/92) Sheet 1 of 3

Form PTO-1449				Attorney's Docket No. 128019-203801 Application Serial No. 09/700,101					
			Applican	Applicant(s) Gary D. GLICK, et al.					
INFORMATION DISCLOSURE STATEMENT									
, , , , , , , , , , , , , , , , , , , ,				Filing Da	Filing Date: November 8, 2000 Group Art Unit: Unassigned				
		veral sheets i		110 1045EVE	MACHINEN SAN SAN SAN SAN SAN SAN SAN SAN SAN SA		70 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -		
Examiner	Ref.	Date	Document No.	Name	DOGUMENTS.	Class	Subclass	Filing Date	
Initials	No.			1144		Ciass	Jubilass	(if appropr	
	1.	02/28/1978	4,076,823	Wade, et al					
	2.	08/29/1978	4,110,337	Szarvasi)	%	
	3.	01/22/1985	4,495,101	Klaubert, e	tal. OLA			10	
	4.	06/14/1988	4,751,223	Glamkowsi	ci, et al.	18	4	C. T.	
	5.	08/20/1991	5,041,438	Hsu	IAN O		6	7	
	6.	06/28/1994	5,324,726	Bock, et al.	MW 0 8 2001 2		WITCH 1650 PC NO	l (\	
	7.	01/28/1997	5,597,915	Chambers,	et by		6		
	8.	07/07/1998	5,776,946	McGeer, et	al. A DEMARK OFF		P.		
	9/	01/19/1999	5,861,380	Gyorkos, et	ui.		E		
	10.	12/21/1999	6,004,942	Firestein, e	t al.				
W	11.	06/27/2000	6,080,588	Glick					
字具有機關	THE STREET STREET			REIGNIPATIE	NT DOCUMENTS !!!		Hall Strike	SCHOOL SECTION	姚博。
Examiner	Ref.	Date	Document No.	Name		Class	Subclass	Transla	rtion
Initials	No.	00/04/0000	140 0040000	207				YES	NO
S	12.	06/04/2000	WO 00/19200	PCT					and the second s
							Provide (1971)		r els
Examiner	Ref.	Title	Sandanis	aumor _{fi} uue _{fi} o	are, belintentiballea (etc.)				K WE
Initials	No.	11						,	
IM	13.	Adachi, M., et al., "Aberrant Transcription Caused by the Insertion of an Early Transposable Element In an Intron of							
V		Fas Antigen	Gene of Ipr Mice," Pro	c. Natl. Acad.	Sci. USA - 90:1756-1760 (1	993) —			
	14.	Adelman, N.	E., et al., "Treatment o	f (NZB X NZW	F1 Disease with Anti-I-A Mo	onoclonal Ai	ntibodies," J	. Exp. Med	,
	15.	158:1350-13		dataviaity of /	Ascorbic Acid and Dehydro		ld la Nassach	4 /01/	N 0111
	''	and Neuroed	todermal (SK-N-LO) C	ells." <i>Anticani</i>	ce <i>r Research —</i> <u>14</u> :221 - 228 (ascordic Aci	ia in Neurobi	astoma (SK-	N-5H)
	16.	Beale, P.J.,	et al., "BCL-2 Family Pr	rotein Express	lon and Platinum Drug Res	Istance in O	varian Carci	noma. ⁿ Britis	sh
		Journal of C	ancer – <u>82(</u> 2):436-440 ((2000) /				•	
1	17.	Boojamra, C	.G., et al., "Solid-Phase	e Synthesis of	1,4-Benzodiazepine-2,5-Di	ones. Libra	ry Preparatio	n and	
	40				Chem 62:1240-1256 (199)		<u></u>		
	18.	J. Am. Chem	et al., "A General and l <u>1. Soc. – 114</u> :10997-109	Expedient Mei 198 (1992) - ✓	hod for the Solid-Phase Sy	nthesis of 1	,4-Benzodiaz	epine Deriva	rtives,"
	19.				and Chemical and Biologic	ral Evaluation	n of a 1 A.P.	nzodiazoni-	
		Library," Pro	oc. Natl. Acad. Sci. USA	4 - <u>91</u> :7408-47	12 (1994) /			·	
	20.				tivation Through High-Affir	nity Binding	Sites," Onco	gene – 8:30	05-3011
		(1993)				_	-	_	
	21.				dels of Systemic Autoimm	unity and Ly	mphoprolife	rative Diseas	se,"
- \/ \	22.		mmunol. – 9:243-269 (*		Science - 282:2000-2001 (4000\ 4			
X	23.	Desoize B	"Anticancer Drug Resi	stance and in	hibition of Apoptosis," <i>Ani</i>	Cancar Poss	arch _ 14.22	01-2204 /400	<u> </u>
/ ^			- 3.200 Plug Itosi	VIETO GITO III	or Apoptosis, Milit	Patrol Mase	arun - <u>14</u> .22	3 1-EE34 (133	7) /
EXAMINE	R:				DATE CONSIDERED		3130	6	
EXAMINER:	Initial I	citation consid	dered, whether or not the	ne citation con	forms with MPEP 609. Drav	w a line thro			onforma
not conside	red. Inc	lude a copy of t	this form with next com	munication to	applicant.			_	
154157.1					9				
193696v1									

Form PTO-1449			Attorney's Docket No. 12	8019-203801	Application	Serial 103. /090700,101		
			Applicant(s)		N			
INFO	RMATIO	N DISCLOSURE STATEMENT		Gary D. GLIC		S JAN OR S		
			Filing Date: November 8	3, 2000	Group Art	it: Unassigned		
	use sev	eral sheets if necessary)		2-0		COMPANIE AND		
		OUŅER dialidiniev	hor (litle date pertinentipa	065,0(G));;;; :	J 2 100			
TY	24.	Doble, A., et al., "Labelling of Periphe Anatomical and Subcellular Distributi	ral-Type Benzodiazepine Bl	inding Sites in Hu in - 18:49-61 (19)	ıman Brain v 87)	ינח (און אין אין אין אין אין אין אין אין אין אי		
-V	25.	Donadio, J.V., et al., "Immunosuppres	sive Drug Therapy in Lupus	s Nephritis," Ame	rican Journ	al of Kidney Diseases -		
		21(3):239:250 (1993)						
	26.	Ermak, T.H., et al., "Treatment of Muri 61(4):447-456 (1989)	ne Lupus with Monocional .	Antibody to L314	i," Labora(og	y investigation 4		
	27.	Gallant J.E. et al. "incidence and Na	ural History of Cytomegalo	virus Disease in l	Patients with	Advanced Human		
		Immunodeficiency Virus Disease Trea	ited with Zidovudine," The .	Journal of Infecti	ous Disease	s <u>-2166</u> :1223-1227 (1 0 92) /		
1	28.	Garcia-Calvo, M., et al. "Inhibition of I of Biological Chemistry – 273(49):326	luman Caspases by Pepud 08.32613 (1998)	e-Based and Mac	romolecular	innigitors, the Journal		
	29.	Gorczyca, W., et al., "Induction of DN	A Strand Breaks Associated	d with Apoptosis	During Treat	tment of Leukemias,"		
		Leukemia - 7(5):659-670 (1993)				·		
	30.	Gordon, C., et al "Chronic Therapy v	vith Recombinant Tumor Ne	ecrosis Factor-α	in Autoimmu	INE NZBINZW F1 MICE,"		
	31.	Clinical Immunology and Immunopat Gordon, E.M., et al., "Applications of	nology – <u>52</u> :421-454 (1909) Combinatorial Technologie	s to Drug Discov	ery. 2. Comi	binatorial Organic		
	J1.	Synthesis, Library Screening Strateg	es, and Future Directions,"	Journal of Medic	cinal Chemis	etry – <u>37(</u> 10):1385-1401		
	32.	Hahn, B.H., et al., "Influence of Cyclo Neoplasia in NZB/NZW Mice," Arthrit	phosphamide and Other Im is and Rheumatism – 18(2):	munosuppressiv 145-152 (1975) <i>~</i>	e Drugs on I	mmune Disorders and		
	33.	Hang, L., et al., "A Spontaneous Rhe	umatoid Arthritis-Like Disea	ase in MRL/1 Mice	s," J. Exp. M	ed. – <u>155</u> :1690-1701 (1982)		
	34.	Horowitz, R.E., et al., "Cyclophospha		Systemic Lupus E	rythematosu	ıs," Laboratory		
Investigation - 21(3):199-206 (1969) ~ 35. Itoh, N., et al., "The Polypeptide Enco			ded by the cDNA for Huma	n Celi Surface Ar	ntigen Fas Ca	an Mediate Apoptosis,"		
	33.	Cell - 66:233-243 (1991)						
	36.	Koopman, W.J., et al., "The MRL-lpr// Rheumatology - Suppl 75:284-289 (1	988) 🖍		_			
	37.	(1992)	ew Category of Oncogenes: Regulators of Cell Death," Blood - 80(4):879-886					
	38.	Gynecologic Opcology - 70:398-403	in Ovarian Carcinoma and Modulates Chemotherapy-Induced Apoptosis," 3 (1998)					
	39.	Los, M., et al., "The Role of Caspase Knockout Mice," <i>Immunity</i> – 10:629-	es in Development, immunity, and Apoptotic Signal Transduction: Lessons from					
	40.	Luria, et al., "General Viology - 3rd et	lition, pp. 436-446 (1978) –	Eds. John Wiley	& Sons, Nev	v York 🗸		
	41.	Marino, M., et al., "Prevention of Sys	temic Lupus Erythematosu:	s in MR∐ <i>ipr</i> Mice	by Adminis	tration of an		
	42.	Immunoglobulin-Binding peptide," A McDonnell, T.J., et al., "Progession t	rom I vmnhoid Hyperniasia	to High-Grade M	alignant Lyn	nphoma in Mice		
	42.	Transgenic for the t(14:18)." Nature	- 349:254-256 (1991)	<u> </u>				
	43.	Nagata, S., "Human Autoimmune Ly Lesson from the Mouse Model," J. h	mphoproliferative Syndrom	ie, a Defect in the	Apoptosis-I	nducing Fas Receptor: A		
 	44.	Okuyama, H., et al., "Analysis of Def	ective Delayed-Type Hypen	sensitivity in Auto	oimmune Mi	ce Bearing Ipr Gene," Clin.		
	/	Exp. Immunol 63:87-94 (1986) /						
T T	45.	Okuyama, H., et al., "Effect of Cyclo Autoimmune-Prone MRL Mice," Int.	phosphamide Pretreatment Arch. Aliergy Appl. immund	on Defective Del ol. – <u>88</u> :394-401 (1	ayed-Type H 989) /	ypersensitivity in		
EXAMIN	ER:		DATE CON	ISIDERED:	31 30	106		
EXAMINER not consid	R: Initial	if citation considered, whether or not the clude a copy of this form with next comm	e citation conforms with MP nunication to applicant.	EP 609. Draw a II	ne through ti	he citation if not in conforma		
154157.1			· · · · · · · · · · · · · · · · · · ·					
193696v1								
1								

				Form PTO-1449	Attorney's Docket No. 12	28019-203801	Application Serial No. 09/700,101		
1		NEC	DRANTI	ON DISCLOSURE STATEMENT	Applicant(s)				
ŀ		Mrc.		ON DISCLOSURE STATEMENT		Gary D. GLi	CK, et al.		
		(use several sheets if necessary)			Filing Date: November	8, 2000	Group Art Unit: Unassigned		
	据标		EM TO	OTHER	DOCUMENTS (Continuat	lion)			
ļ		lia.		是	hor title date pertinention	aes etclia a se			
	7		46.	Ozols, R.F., "Paclitaxel Plus Carboplated 2):84-89 (1999)	tin in the Treatment of Ova	rian Cancer," Sen	ninars in Oncology – <u>26</u> (1)(Supp.		
	 47. Pestell, K.E., et al., "Characterisation of the P53 Status, BCL-2 Expression and Radiation and Platinum Drug Sen of a Panel of Human Ovarian Cancer Cell Lines," Int. J. Cancer – 77:913-918 (1998) 48. Raynaud, F.I., et al., "Intracellular Metabolism of the Orally Active Platinum Drug JM216: Influence of Glutathion Levels," Br. J. Cancer – 74(3):380-386 (1996) 								
-									
		49. Russell, J.H., et al., "Mature T Cells of Autoimmune Ipr/Ipr Mice have a Defect in Antigen-Stimulated Suicide," Proc Natl. Acad. Sci. USA – 90:4409-4413 (1993)							
			50.	Sakata, K., et al., "Role of Fas/Fasl. Ini Immunology and Immunopathology -	<u>87(1):1-7 (1998)</u>				
	NP.	7	51.	Sandstrom, P.A., et al., "Autocrine Pro Line in Serum-Free Medium," <i>Proc. Na</i>	duction of Extracellular Ca	atalase Prevents A	poptosis of the Human CEM T-Cell		
	J · -		52.	Schoemaker, H., et al., "Specific High- Pharmacology and Experimental There	Affinity Binding Sites for [3	H)Ro5-4864 in Ra	t Brain and Kidney," The Journal of		
٦١٠	B D MA			Schwab, M., et al., "Amplified DNA with Neuroblastoma Cell Lines and a Neuro	Limited Homology to my	c Cellular Oncoge	ne is Shared by Human		
	E TRAD	EMP		Scott, C.F., et al., "Comparison of Anti Mice," The Journal of Immunology – 1	gen-Specific T Cell Respon	nses in Autoimmu	ne MRL/mp-lpr/lpr and MRL/Mp-+/+		
		Scott, C.F., et al., "Comparison of Antigen-Specific T Cell Responses in Autoimmune MRL/mp-lpr/lpr and MRL/Mp-Mice," The Journal of Immunology – 132(2):633-639 (1984) 55. Sentman, C.L., et al., "bcl-2 Inhibits Multiple Forms of Apoptosis but not Negative Selection in Thymocytes," Cell – 67:879-888 (1991)							
			56.	Sheppard, R.C., et al., "Acid-Labile Res Protein Res. – 20:451-454 (1982)					
			57.	Stevens, S.Y., et al., "Non Nucleic Acid Chemistry," J. Am. Chem. Soc. – 118:	Inhibitors of Protein-DNA 10650-10651 (1996)	Interactions Ident	ified Through Combinatorial		
	·		58.	Sugimoto, T., et al., "Determination of Leukemia-Lymphoma Cell Lines by a F	Cell Surface Membrane An	tigens Common to	o Both Human Neuroblastoma and		
			59.	Swanson, P.C.,et al., "High Resolution Immunology – 152(5):2601-2612 (1994)	Epitope Mapping of an Ant	ti-DNA Autoantibo	ody Using Model DNA Ligands," J.		
			60.	Swanson, P.C., et al., "Ligand Recogni (1996)	tion by Murine Anti-DNA A				
			61.	Takahashi, T., et al., "Generalized Lym Cell –76:969-976 (1994)					
			62.	Theofilopoulous, A.N., et al., "Murine N 390 (1985)	lodels of Systemic Lupus E	Erythematosus,"	Advances in Immunology – <u>37</u> :269-		
L			63.	Thompson, C.B., "Apoptosis in the Pat	hogenesis and Treatment	of Disease," Scien	rce - 267:1456-1462 (1995)		
			64.	Watanabe-Fukunaga, R., et al., "Lymph Mediates Apoptosis," <i>Nature</i> – <u>356</u> :314	oproliferation Disorder In I -317 (1992)	Mice Explained by	Defects in Fas Antigen that		
L		\rightarrow	65.	White, E., "Life, Death, and the Pursuit	of Apoptosis," Genes & De	evelopment - 10:1	-15 (1996)		
L		66. Wu, G.Y., et al., "Receptor-Mediated in Vitro Gené Transformation by a Soluble DNA Carrier System," The Journal of Biological Chemistry — 262(10):4429-4432 (1987)							
L		\dashv	67.	Wyllie, A.H., "The Genetic Regulation of	f Apoptosis," Current Opin	nion in Genetics &	Development - 5:97-104 (1995)		
H	-17		68	Zamzami, N., et al., "Mitochondrial Con	trol of Nuclear Apoptosis."	" J. Exp. Med 18	3:1533-1544 (1996)		
-	V		69.	Zoratti, M., et al., "The Mitochondrial Pe	ermeability Transition," Bio	ochimica et Bloph	ysica Acta - 1241:139-176 (1995)		
E	EXAMI	NEI	R:		DATE CONS	IDERED: 21	70/01/		
E	XAMINI ot cons	ER: ider	Initial if ed. Inclu	citation considered, whether or not the ci	tation conforms with MDED	,,,			
L.,	54157.1								
-	93696v								
1									